353 related articles for article (PubMed ID: 32238579)
1. CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells.
Smith NA; Coleman CB; Gewurz BE; Rochford R
J Virol; 2020 May; 94(11):. PubMed ID: 32238579
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cell-mediated transfer infection.
Shannon-Lowe C; Rowe M
PLoS Pathog; 2011 May; 7(5):e1001338. PubMed ID: 21573183
[TBL] [Abstract][Full Text] [Related]
3. Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands.
Janz A; Oezel M; Kurzeder C; Mautner J; Pich D; Kost M; Hammerschmidt W; Delecluse HJ
J Virol; 2000 Nov; 74(21):10142-52. PubMed ID: 11024143
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.
Busse C; Feederle R; Schnölzer M; Behrends U; Mautner J; Delecluse HJ
J Virol; 2010 Jan; 84(2):1139-47. PubMed ID: 19889766
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways.
D'Addario M; Libermann TA; Xu J; Ahmad A; Menezes J
J Mol Biol; 2001 May; 308(3):501-14. PubMed ID: 11327783
[TBL] [Abstract][Full Text] [Related]
6. CD21-independent Epstein-Barr virus entry into NK cells.
Lee JH; Choi J; Ahn YO; Kim TM; Heo DS
Cell Immunol; 2018 May; 327():21-25. PubMed ID: 29499908
[TBL] [Abstract][Full Text] [Related]
7. The Epstein-Barr virus-binding site on CD21 is involved in CD23 binding and interleukin-4-induced IgE and IgG4 production by human B cells.
Henchoz-Lecoanet S; Jeannin P; Aubry JP; Graber P; Bradshaw CG; Pochon S; Bonnefoy JY
Immunology; 1996 May; 88(1):35-9. PubMed ID: 8707347
[TBL] [Abstract][Full Text] [Related]
8. Patterned entry and egress by Epstein-Barr virus in polarized CR2-positive epithelial cells.
Chodosh J; Gan Yj; Holder VP; Sixbey JW
Virology; 2000 Jan; 266(2):387-96. PubMed ID: 10639323
[TBL] [Abstract][Full Text] [Related]
9. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).
Young KA; Chen XS; Holers VM; Hannan JP
J Biol Chem; 2007 Dec; 282(50):36614-25. PubMed ID: 17925391
[TBL] [Abstract][Full Text] [Related]
10. Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor.
Ogembo JG; Kannan L; Ghiran I; Nicholson-Weller A; Finberg RW; Tsokos GC; Fingeroth JD
Cell Rep; 2013 Feb; 3(2):371-85. PubMed ID: 23416052
[TBL] [Abstract][Full Text] [Related]
11. Characterization of an Epstein-Barr virus receptor on human epithelial cells.
Birkenbach M; Tong X; Bradbury LE; Tedder TF; Kieff E
J Exp Med; 1992 Nov; 176(5):1405-14. PubMed ID: 1383386
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Epstein-Barr virus (EBV) receptor CD21 on peripheral B lymphocytes of long-term EBV- adults.
Jabs WJ; Paulsen M; Wagner HJ; Kirchner H; Klüter H
Clin Exp Immunol; 1999 Jun; 116(3):468-73. PubMed ID: 10361236
[TBL] [Abstract][Full Text] [Related]
13. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells.
Turk SM; Jiang R; Chesnokova LS; Hutt-Fletcher LM
J Virol; 2006 Oct; 80(19):9628-33. PubMed ID: 16973566
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice.
Coleman CB; Lang J; Sweet LA; Smith NA; Freed BM; Pan Z; Haverkos B; Pelanda R; Rochford R
J Virol; 2018 Nov; 92(21):. PubMed ID: 30089703
[TBL] [Abstract][Full Text] [Related]
16. Human T lymphotropic virus-type I Tax induction of CD21/Epstein-Barr virus receptor expression on T cells and its significance in leukemogenesis of adult T cell leukemia.
Ohtsubo H; Arima N; Matsushita K; Hidaka S; Fujiwara H; Arimura K; Kukita T; Fukumori J; Matsumoto T; Eizuru Y; Tanaka H
Exp Hematol; 1997 Nov; 25(12):1246-52. PubMed ID: 9357968
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus (EBV) infection in B-cell non-Hodgkin's lymphomas in children: virus latency and its correlation with CD21 and CD23 molecules.
Kasprzak A; Spachacz R; Wachowiak J; Stefanska K; Zabel M
Folia Histochem Cytobiol; 2007; 45(3):169-79. PubMed ID: 17951165
[TBL] [Abstract][Full Text] [Related]
18. IL-4 increases CD21-dependent infection of pulmonary alveolar epithelial type II cells by EBV.
Malizia AP; Egan JJ; Doran PP
Mol Immunol; 2009 May; 46(8-9):1905-10. PubMed ID: 19193442
[TBL] [Abstract][Full Text] [Related]
19. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
[TBL] [Abstract][Full Text] [Related]
20. An Epstein-Barr virus susceptible immature T-cell line, WILL4, established from a patient with T-lymphoblastic lymphoma bearing CD21 and a clonal EBV genome.
Hosoi H; Imadome KI; Tamura S; Kuriyama K; Murata S; Yamashita Y; Mushino T; Oiwa T; Kobata H; Nishikawa A; Nakakuma H; Hanaoka N; Isobe Y; Ohshima K; Sonoki T
Leuk Res; 2017 Apr; 55():1-5. PubMed ID: 28110206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
